Haemonetics Corp Earnings

Haemonetics Corp’s revenue fell -4.4% since last year same period to $321.39Mn in the Q2 2025. On a quarterly growth basis, Haemonetics Corp has generated -2.78% fall in its revenue since last 3-months.

Haemonetics Corp’s net profit fell -11.32% since last year same period to $34.03Mn in the Q2 2025. On a quarterly growth basis, Haemonetics Corp has generated -41.31% fall in its net profits since last 3-months.

Haemonetics Corp’s net profit margin fell -7.24% since last year same period to 10.59% in the Q2 2025. On a quarterly growth basis, Haemonetics Corp has generated -39.63% fall in its net profit margins since last 3-months.

Haemonetics Corp’s price-to-earnings ratio after this Q2 2025 earnings stands at 15.4.

Haemonetics Corp’s earning per share (EPS) estimates for the current quarter stand at 1.11 - a 8.82% jump from last quarter’s estimates.

Haemonetics Corp’s earning per share (EPS) estimates for the current year stand at 1.11.

Haemonetics Corp’s earning per share (EPS) jumped 7.84% since last year same period to 1.1 in the Q2 2025. This indicates that the Haemonetics Corp has generated 7.84% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Haemonetics Corp’s return on assets (ROA) stands at 0.07.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Haemonetics Corp’s return on equity (ROE) stands at 0.18.